Biomodal has released integrated DNA sequencing workflows that extract genetic, epigenetic, and structural information from circulating cell-free DNA in a single test, improving the ability to detect cancer at earlier stages and monitor treatment response. The technology addresses technical limitations in distinguishing DNA modifications and detecting specific mutations that conventional conversion-based methods miss.
Key Points
- Single workflow captures genetic, epigenetic, and fragmentomic data from cfDNA simultaneously
- Disambiguates 5mC and 5hmC modifications; detects C>T mutations with higher confidence
- Combining multiple signal types lowers detection thresholds for early cancer and minimal residual di
Longevity Analysis
Early detection fundamentally changes cancer outcomes and extends healthspan by intercepting disease before it progresses to symptomatic stages. This technology works by gathering more granular information from a single blood sample—multiple independent signals that, when analyzed together, improve classification specificity and detection sensitivity. The ability to reliably distinguish epigenetic modifications and detect specific mutation patterns addresses a critical gap in current liquid biopsy methods, enabling earlier intervention windows when treatment burden is typically lower and prognosis improves. For individuals pursuing longevity-informed health maintenance, this represents a shift from reactive disease management to proactive early-stage identification.
Original published by LT Wire.